Oral Medication Approved for MS in Canada


Oral Medication Approved for MS in Canada

Multiple Sclerosis treatment is bound to revolutionize in Canada as drug-maker Novartis Pharmaceutical Canada Inc. announced on Thursday that the first oral medicine for the condition has been approved for use by some patients in the country. The medication will basically help in providing treatment for the symptoms of MS.

The medicine has been named Gilenya and will be available for sale from the 1st of April at pharmaceutical stores across the nation. The medicine will be available for people who have tried another treatment for the condition with poor results.

The chemical name for Gilenya is fingolimod and it will be used for people with the relapsing-remitting form of the condition. According to the figures available, the disease ends up affecting an astounding 75,000 Canadians. People with this variety of the condition are likely to experience new symptoms with severity of older symptoms worsening.

Gilenya will help in reducing flare-ups of people suffering from multiple sclerosis and will also help in reducing the rate of progress. Each capsule of Gilenya contains 0.5 milligrams of the drug and is the most convenient treatment for MS in Canada.

Talking about the development, a Neurologist from Toronto, Dr. Daniel Selchan, said: "The approval of Gilenya is a significant milestone for the Canadian MS community".

Latest News

United’s New CEO Oscar Muñoz Aims at Improving relation with Workers
The September Job Number Hint at a Sluggish Patch
First Data Launches its IPO, Targets to Raise Up to $3.7 Billion
ConAgra’s Head Quarter Move Announcement gets Positive but ‘Muted’
Dunkin’ Donut Franchisee Plans to Close One Hundred Stores
Mr. Munoz New CEO of United Airline says Things will Improve under his Leadershi
Reportedly Walmart is Planning to Trim Hundreds of Jobs at its Bentonville
The Government Looking Deeper into Safety Issues; Transportation Secretary
Data Shows Rise in Local Home Prices Slow Down but Surpass the U.S. Average
Oil Futures Drop as U.S. Inventories Show Build-up Surpassing Analysts
Gap’s, Old Navy Head, to Become the new CEO of Ralph Lauren Corp.
Majority of UAW Workers at Warren Truck and Mack Engine Plant Vote in Favor